We are holding steady to our fair value estimate and wide moat rating for Pfizer PFE following first-quarter results that largely matched our expectations. The company is tracking well to meet its ...

Pfizer's financial results have been subpar in recent years. The company's newer products are starting to come into their own. The drugmaker's pipeline could lead to even more important brand-new ...

These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now.

・Pfizer provides Covid vaccine called Comirnaty in addition to an antiviral medication used to treat COVID-19 called Paxlovid. ・In 2026, the company expects the revenue to fall further or stay at 2025 ...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close ...

Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track. That kind of price decline doesn't happen by accident, which means you need to carefully ...